A model to predict a risk of allergic rhinitis based on mitochondrial DNA copy number

a.sfakia shared this article with you from Inoreader A model to predict a risk of allergic rhinitis based on mitochondrial DNA copy number Via http://link.springer.com/journal/405,European archives of oto-rhino-laryngology,The European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino Eur Arch Otorhinolaryngol. 2022 Mar 29. doi: 10.1007/s00405-022-07341-7. Online ahead of print. ABSTRACT PURPOSE: To determine whether mitochondrial DNA copy number (mtDNA-CN) is associated with allergic rhinitis (AR), and further establish a nomogram model for the early diagnosis of AR. METHODS: We carried out a case-control study involving a total of 134 subjects, including 66 healthy controls and 68 AR patients. The mtDNA-CN in peripheral blood of all subjects was detected by real-time fluorescence quantitative polymerase chain reaction, and general information of patients was recorded. And, least absolute shrinkage selection operator (LASSO) regression was used to screen clinically significant variables, which were substituted into a logistic regression analysis to determine independent risk factors. Next, a nomogram model was developed for the risk prediction of AR. Then, internal validation was performed with the bootstrap resampling. Ultimately, the clinical benefit and validity of the nomogram were assessed by receiver operating characteristic (ROC) curve, bias-corrected curve, and decision curve analysis (DCA). RESULTS: MtDNA-CN and total IgE were determined as independent risk factors of AR. The final model achieved an area under the ROC curve (AUC) of 0.869, and the DCA curve demonstrated that the nomogram was clinically beneficial for practical application. CONCLUSION: An increase of the mtDNA-CN was linked to the occurrence risk of AR. The nomogram prediction model based on mtDNA-CN showed the potential clinical utility in improving risk prediction and providing new insights for exploring the pathogenesis of AR. PMID:35348857 | DOI:10.1007/s00405-022-07341-7 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

A comparison between sniffing and blowing for olfactory testing before and after laryngectomy

a.sfakia shared this article with you from Inoreader A comparison between sniffing and blowing for olfactory testing before and after laryngectomy Via http://link.springer.com/journal/405,European archives of oto-rhino-laryngology,The European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino Eur Arch Otorhinolaryngol. 2022 Mar 29. doi: 10.1007/s00405-022-07343-5. Online ahead of print. ABSTRACT PURPOSE: Olfactory dysfunction occurs after laryngectomy due to the loss of nasal airflow and inability to sniff. However, the reason for the loss of olfactory function after laryngectomy is unclear on evaluation with sniffing type tests performed individually. It is expected that the sensorineural olfaction remains, and the results of the sniffing test would be negative, while that of the odour-blowing test would be positive. Therefore, the aim of this study was to investigate both tests and prove normal olfaction in the patients. METHODS: Patients who had undergone laryngectomy were evaluated using the T&T olfactometer for odour-sniffing tests, Jet Stream Olfactometer (JSO) for odour-blowing tests, and visual analogue scale (VAS). Evaluations were performed pre-operatively, and 1 month, 6 months, and 1-year post-laryngec tomy. RESULTS: Thirty-two patients were included in the study. The median recognition thresholds using the T&T and JSO were 1.4 and 2.2 before surgery, 5.8 and 5.4 at 1 month, 5.8 and 5.2 at 6 months, and 5.8 and 5.0 at 1 year after surgery, respectively. Results of the olfactory threshold test in both T&T and JSO and VAS score were significantly worse after surgery compared to that before laryngectomy (p < 0.05). The degree of increase was significantly smaller with JSO than with T&T (p < 0.05). CONCLUSION: While we could not prove normal olfaction in patients after laryngectomy, the odour-blowing test was superior to the odour-sniffing test in detecting patients with residual olfaction. Simply blowing a scent is insufficient to obtain good olfaction; active airflow is crucial for recognizing odours. PMID:35348858 | DOI:10.1007/s00405-022-07343-5 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Prolactinoma

a.sfakia shared this article with you from Inoreader Prolactinoma Via Otolaryngologic Clinics of North America Prolactinomas are the most common secretory tumor of the pituitary gland. Clinical symptoms may be due to prolactin oversecretion, localized mass effect, or a combination of both. Although the mainstay of prolactinoma management is medical therapy with dopamine agonists, endoscopic endonasal or transcranial surgery, radiation therapy, or a combination of these is an important treatment option in select cases. This article discusses prolactinoma phenotypes, clinical presentations, and clinically pertinent medical and surgical considerations when managing these tumors. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Acromegaly

a.sfakia shared this article with you from Inoreader Acromegaly Via Otolaryngologic Clinics of North America Acromegaly results from excessive secretion of insulinlike growth factor-1 and growth hormone, which most commonly occurs because of pituitary somatotrophinoma. Diagnostic features of acromegaly include elevated insulinlike growth factor-1 and growth hormone; lesion on brain MRI; and clinically dysmorphic features, such as soft tissue swelling, jaw prognathism, and acral overgrowth. Transsphenoidal resection is the primary therapy for individuals with acromegaly, even in the cases where gross total resection is not possible because of parasellar extension and cavernous sinus involvement. For recurrent or persistent disease after resection, systemic medications and stereotactic radiosurgery are used. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Giant Pituitary Adenoma – Special Considerations

a.sfakia shared this article with you from Inoreader Giant Pituitary Adenoma – Special Considerations Via Otolaryngologic Clinics of North America Giant pituitary adenomas (GPAs) comprise 5% to 15% of pituitary adenomas, but have higher rates of extrasellar invasion, subtotal resection, surgical morbidity, and recurrence. With the possible exception of giant prolactinomas, GPAs require surgical decompression. On review of 3 decades of case series encompassing 699 microsurgical transsphenoidal (MT), 1060 endoscopic endonasal trans-sphenoidal (EET), and 513 transcranial (TC) patients, gross total resection and recurrence rates were comparable across modalities, but the EET approach had lower perioperative mortality and superior restoration of visual function. Each approach has unique indications. Combined EET-TC approaches for minimizing residual tumor represent another area of study. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Cushing Disease

a.sfakia shared this article with you from Inoreader Cushing Disease Via Otolaryngologic Clinics of North America Cushing disease is a disorder of hypercortisolemia caused by hypersecretion of adrenocorticotropic hormone by a pituitary adenoma and is a rare diagnosis. Cushing disease presents with characteristic clinical signs and symptoms associated with excess cortisol, but diagnosis is difficult and often relies on repeated and varied endocrinologic assays and neuroradiologic investigations. Gold standard treatment is surgical resection of adrenocorticotropic hormone–secreting pituitary adenoma, which is curative. Patients require close endocrinologic follow-up for maintenance of associated neuroendocrine deficiencies and surveillance for potential recurrence. Medications, radiation therapy, and bilateral adrenalectomy are alternative treatments for residual or recurrent disease. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Bladder Cancer Need Not Always Require Radical Cystectomy Bladder Cancer Need Not Always Require Radical Cystectomy

a.l.s.f.akia shared this article with you from Inoreader Bladder Cancer Need Not Always Require Radical Cystectomy Bladder Cancer Need Not Always Require Radical Cystectomy Via Medscape Hematology-Oncology Headlines Researchers involved in a large cohort study from three major institutions are calling for broader use of trimodal therapy for muscle-invasive bladder cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.